COMMUNIQUÉS West-GlobeNewswire

-
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million
14/04/2025 -
SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025
14/04/2025 -
Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock
14/04/2025 -
Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025
14/04/2025 -
NeuroPace Provides Update on Tariff Status
14/04/2025 -
Kestra Medical Technologies Reports Third Quarter Fiscal 2025 Financial Results
14/04/2025 -
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
14/04/2025 -
IBA – ACQUISITION OF OWN SHARES
14/04/2025 -
IBA – ACQUISITION D’ACTIONS PROPRES
14/04/2025 -
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
14/04/2025 -
Epilepsy Community Unites to Oppose Cuts to Crucial Federal Epilepsy Programs
14/04/2025 -
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
14/04/2025 -
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease
14/04/2025 -
AB Science reçoit un avis d’acceptation pour le brevet américain courant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose
14/04/2025 -
Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
14/04/2025 -
Ipsen - Mars 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
14/04/2025 -
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
14/04/2025 -
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
14/04/2025 -
Valneva reçoit la première autorisation de mise sur le marché pour IXCHIQ® dans un pays où le chikungunya est endémique
14/04/2025
Pages